| Literature DB >> 24900604 |
Sunkyung Lee1, Jong-Hwan Song1, Chul Min Park1, Jin-Seok Kim1, Ji-Hye Jeong1, Woo-Young Cho2, Dong-Chul Lim2.
Abstract
Octahydroindene was identified as a novel scaffold for protease activated receptor 1 (PAR1) antagonists. Herein, the 2-position (C2) was explored for structure-activity relationship (SAR) studies. Compounds 14, 19, and 23b showed IC50 values of 1.3, 8.6, and 2.7 nM in a PAR1 radioligand binding assay, respectively, and their inhibitory activities on platelet activation were comparable to that of vorapaxar in a platelet rich plasma (PRP) aggregation assay. This series of compounds showed high potency and no significant cytotoxicity; however, the compounds were metabolically unstable in both human and rat liver microsomes. Current research efforts are focused on optimizing the compounds to improve metabolic stability and physicochemical properties as well as potency.Entities:
Keywords: Octahydroindene; PAR1 antagonist; PRP aggregation; antiplatelet; bleeding
Year: 2013 PMID: 24900604 PMCID: PMC4027540 DOI: 10.1021/ml400235c
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345